DOCSLIB.ORG

On a Fourth Order Pseudoparabolic Equation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
On a Fourth Order Pseudoparabolic Equation Proc. Pakistan Acad. Sci. 42(3): 187-193.2005 ON A FOURTH ORDER PSEUDOPARABOLIC EQUATION Ye. A. Utkina and A. Maher Department of Mathematics,Faculty of Science, Department of Differential Equations, Kazan State University,18 Kremlyovskaya St., Kazan, 420008, Russia, and Assiut University, 71516, Egypt Received February 2005, accepted March 2005 Communicated by Prof. Dr. Q. K. Ghori Abstract: The present paper is devoted to investigation of the Goursat problem of a fourth order psedudoparabolic equation, with the help of Riemann function. Keywords: Partial differential equations, Goursat problem, Riemann function AMS Subject Classification: 35B, 35J, 35Q. Introduction 2 uy x, y0 \1 x xq , \ ,\1 C q , In the domain D ^`x0 x x1, y0 y y1 y p >@y0, y1 , xq >@x0, x1 . (2) we consider the equation Here we assume the following condition as L u u xxyy a21u xxy a12u xyy satisfied: a u a u a u a u 11 xy 20 xx 02 yy 10 x c y x , y x , c x y . M 0 \1 0 M 0 \ 0 \ 0 M1 0 i j a01u y a00u f ,aij C D , f 22 Formulation of the problem C i 0,1,2, j 0,1,2 , We will be searching for the above- (1) mentioned function u(x‘ y) with the help of the where the classCk l means the existence and conti- Riemann function, which is defined as the solution of the integral equation nuity for all derivatives r 0,...k;s 0,...,l . y w i j v x, y a x,W y W a x,W We will call the solution of the class ³ >@21 20 wx iwy j K C D i 0,1,2, j 0,1 as regular. The equation (1) is x v x,W dW a t, y the generalization of the Bussineska-Lyava equation ³ > 12 that describes longitudinal waves in a thin [ elastic shaft with allowance for the effects of x y the crosswise inertia. In this paper we study x t a t, y v t, y dt 02 @ ³ ³ the Goursat problem which consists of finding [ K of the function 2 2 1 0 0 1 a t,W x t a t,W y W a t,W uɋ D ɋ D p ɋ Dq , which in D > 11 01 10 ̓is a solution (1) and satisfies the following x t y W a t,W v t,W dWdt 1. (3) boundary conditions: 00 @ By virtue of [1], it exists and is unique. In u x0, y M y ,ux x0, y M1 y , y p , cases where it is necessary to emphasize the 2 dependence of v ̓not only on (x‘ y), but also on M,M1 C p ;u x, y0 \ x , [,K , we will indicate it, as usually, R x, y;[,K . Fourth order pseudoparabolic equation 188 Here we should note that v ̓does not coincide Q Py a20R ; with R as in ҏ[2-5]. Thus, here R x, y; x, y 1, T R a R a R a R ; while in the mentioned papers R x, y; x, y 0 . xy 21 x 12 y 11 However, v x, y remains the solution of the P Ry a21R ; equation adjoint to (1), namely, K N a R ; * x 02 L v vxxyy a21v xxy a12v xyy a11v xy F1 Ty a20R x a10R ; a20v xx a02v yy a10v x a01v y a00v 0. F2 Tx a02R y a01R . Let us now solve the Goursat problem (G). First, we will prove the auxiliary result. This enables us to write (4) in the form: Let u x, y belong to the class of the uR xxyy RL u >@uP xxy unknown functions of the Goursat problem. Then the following identity is true: >@uN xyy >@uQ >@uK yy >@uT xy xx uR { RL u u R a R xxyy > y 21 @xxy >@>@uF1 x uF2 y >@u x R y xy >@>u R a R u R a R x 12 xyy yy 21 y u R u a R u a R >@yy x y 21 x 20 x x a20 R @xx >@u Rxx a12 R x a02 R yy uR u a R u a R . (5) >@xxy x 12 y 02 y y u R a R a R a R > xy 21 x 12 y 11 @xy Let us collect the auxiliary identities which will be needed during the integration of (5). >u Rxyy a21R xy a12 R yy a11R y N x, y, x, y { P x, y, x, y { T x, y, x, y { 0 , a20 R x a10 R @ >u Rxxy a21R xx x Q x, y, x,K { K x, y,[, y { a R a R a R a R + 12 xy 11 x 002 y 01 @y F1 x, y, x,K { F2 x, y,[, y { 0 . For example, let us verify that N x,y,x,y {0. u x Ry ^u yy Rx ` ^uRxxy ` ^u y a21R x ` + xy x y x In reality, we put in (3) K y to obtain u a R u a R u a R , (4) x ^ x 12 y `y ^` 20 x x ^ 02 y `y v x, y >@a12 t, y x t a02 t, y v t, y dt 1 ³ [ where arguments of a i 0,1,2; j 0,1,2 are ij Differentiating this relation with respect to x x, y , and at R ̓and its derivatives- x, y;[,K . we obtain The relation (4) is checked directly. Let us put x . vx x, y a12 x, y v x, y ³ a02 t, y v t, y dt 0 [ N Rx a12 R ; Now let[ x . Hence 189 Ye. A. Utkina and A. Maher y vx x, y a12 x, y v x, y 0 . u R u a R u a R x ,K dK ³ > KK x K 21 x 20 x @ 0 Let us now start finding u x, y . We y0 change in (5) the roles of the variables x with[ u a12 R y x0 , y and y with K and calculate the integral in the right x uR u a R u a R [, y d[. and left parts in the bounds x0 d [ d x , ³ > [[y [ 12 y 02 y @ 0 x0 y0 dK d y : In view of (2), the last equality can be written in the form u xy x, y u xy R x, y0 u x Ry x, y0 u R x, y uR x, y y x 0 xy 0 c uxy x, y \1 x R x, y0 \ c x Ry x, y0 u xy R x0 , y u x Ry x0 , y u y Rx x0 , y \ x R x, y \ x R x, y 1 x 0 xy 0 uRxy x0 , y u xy R x0 , y0 c c u x Ry x0 , y0 u y Rx x0 , y0 uRxy x0 , y0 M1 y R x0 , y M1 y Ry x0 , y M y Rx x0 , y x y c M y R x , y M y R x , y ³³R [,K; x, y L u dKd[ xy 0 1 0 0 0 x00y M1 y0 Ry x0 , y0 \1 x0 Rx x0 , y0 x y >@u x P x0 , y >@uPx x0 , y >@u x P x, y0 M y0 Rxy x0 , y0 R [,K; x, y L u dKd[ >@uPx x, y0 >@u x P x0 , y0 ³³ x00y M y P x , y M y P x , y \ c x P x, y >@uPx x0 , y0 >u y N @ x0 , y >uN y @ x0 , y 1 0 x 0 0 \ x Px x, y0 M1 y0 P x0 , y0 >@u y N x, y0 >@uN y x, y0 M y0 Px x0 , y0 Mc y N x0 , y >u y N @ x 0 , y 0 >uN y @ x 0 , y 0 M y N y x0 , y \ 1 x N x, y0 \ x N y x, y0 y u Q uQ x ,K dK x N x , y y N x , y ³ >@x x 0 \ 1 0 0 0 M 0 y 0 0 y 0 y x Q x , Q x , d u K uK [ , y d[ uT x , y >@M1 K 0 K M K x 0 K K ³ >@y y 0 >@ 0 ³ y0 x0 y x uT x, y uT x , y uF x ,K dK \ 1 [ K [, y0 \ [ K y [, y0 d[ >@ 0 >@ 0 0 ³ >@1 0 ³ >@ y0 x0 x M y T x0 , y \ x T x, y0 >@uF2 [ , y 0 d[ u x R y x0 , y ³ >@ y x0 M y0 T x0 , y0 M K F1 x0 ,K dK >@u x R y x, y 0 >@u x R y x0 , y 0 ³ y0 >@u y R x x, y 0 >@uR xy x, y 0 x \ [ F [, y d[ u a 21 R x x, y 0 ³ 2 0 x0 M1 y Ry x0 , y \ c x Ry x, y0 M1 y0 Ry x0 , y0 Fourth order pseudoparabolic equation 190 \ 1 x Rx x, y0 \ x Rxy x, y0 y ª x º \ x a R x, y M K R x ,K u3 x, y exp« D1 t, y dt» 21 x 0 ³ > KK x 0 ³ « x0 » y0 ¬ ¼ x t Mc K a21R x x0 ,K M K a20 R x x0 ,K @dK ª ª º º «C y f t, y exp« D t , y dt»dt»; y a R x , y 3 ³ ³ 1 1 M 12 y 0 « x x » ¬ 0 ¬« 0 ¼» ¼ x ª y º \ [ R [, y \ c [ a R u x, y exp« E x,W dW » ³ > [[y 0 12 y 2 ³ 1 (6) y x0 ¬« 0 ¼» y [, y0 \ [ a02 R y [, y0 @d[.
Load more

Recommended publications
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • Consolidated List of Up-Regulated Proteins Expressed at Different Cr (VI) Concentrations at Time Points
    Electronic Supplementary Material (ESI) for Metallomics.
    [Show full text]
  • A Genomic Analysis of Rat Proteases and Protease Inhibitors
    A genomic analysis of rat proteases and protease inhibitors Xose S. Puente and Carlos López-Otín Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Instituto Universitario de Oncología, Universidad de Oviedo, 33006-Oviedo, Spain Send correspondence to: Carlos López-Otín Departamento de Bioquímica y Biología Molecular Facultad de Medicina, Universidad de Oviedo 33006 Oviedo-SPAIN Tel. 34-985-104201; Fax: 34-985-103564 E-mail: [email protected] Proteases perform fundamental roles in multiple biological processes and are associated with a growing number of pathological conditions that involve abnormal or deficient functions of these enzymes. The availability of the rat genome sequence has opened the possibility to perform a global analysis of the complete protease repertoire or degradome of this model organism. The rat degradome consists of at least 626 proteases and homologs, which are distributed into five catalytic classes: 24 aspartic, 160 cysteine, 192 metallo, 221 serine, and 29 threonine proteases. Overall, this distribution is similar to that of the mouse degradome, but significatively more complex than that corresponding to the human degradome composed of 561 proteases and homologs. This increased complexity of the rat protease complement mainly derives from the expansion of several gene families including placental cathepsins, testases, kallikreins and hematopoietic serine proteases, involved in reproductive or immunological functions. These protease families have also evolved differently in the rat and mouse genomes and may contribute to explain some functional differences between these two closely related species. Likewise, genomic analysis of rat protease inhibitors has shown some differences with the mouse protease inhibitor complement and the marked expansion of families of cysteine and serine protease inhibitors in rat and mouse with respect to human.
    [Show full text]
  • Regional Heterogeneity Impacts Gene Expression in the Subarctic Zooplankter Neocalanus flemingeri in the Northern Gulf of Alaska
    ARTICLE https://doi.org/10.1038/s42003-019-0565-5 OPEN Regional heterogeneity impacts gene expression in the subarctic zooplankter Neocalanus flemingeri in the northern Gulf of Alaska Vittoria Roncalli 1,2, Matthew C. Cieslak1, Martina Germano1, Russell R. Hopcroft3 & Petra H. Lenz1 1234567890():,; Marine pelagic species are being increasingly challenged by environmental change. Their ability to persist will depend on their capacity for physiological acclimatization. Little is known about limits of physiological plasticity in key species at the base of the food web. Here we investigate the capacity for acclimatization in the copepod Neocalanus flemingeri, which inhabits the Gulf of Alaska, a heterogeneous and highly seasonal environment. RNA-Seq analysis of field-collected pre-adults identified large regional differences in expression of genes involved in metabolic and developmental processes and response to stressors. We found that lipid synthesis genes were up-regulated in individuals from Prince William Sound and down-regulated in the Gulf of Alaska. Up-regulation of lipid catabolic genes in offshore individuals suggests they are experiencing nutritional deficits. The expression differences demonstrate physiological plasticity in response to a steep gradient in food availability. Our transcriptional analysis reveals mechanisms of acclimatization that likely contribute to the observed resilience of this population. 1 Pacific Biosciences Research Center, University of Hawai’iatMānoa, 1993 East-West Rd., Honolulu, HI 96822, USA. 2 Department of Genetics, Microbiology and Statistics, Facultat de Biologia, IRBio, Universitat de Barcelona, Av. Diagonal 643, 08028 Barcelona, Spain. 3 Institute of Marine Science, University of Alaska, Fairbanks, 120 O’Neill, Fairbanks, AK 99775-7220, USA. Correspondence and requests for materials should be addressed to V.R.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]
  • Protein T1 C1 Accession No. Description
    Protein T1 C1 Accession No. Description SW:143B_HUMAN + + P31946 14-3-3 protein beta/alpha (protein kinase c inhibitor protein-1) (kcip-1) (protein 1054). 14-3-3 protein epsilon (mitochondrial import stimulation factor l subunit) (protein SW:143E_HUMAN + + P42655 P29360 Q63631 kinase c inhibitor protein-1) (kcip-1) (14-3-3e). SW:143S_HUMAN + - P31947 14-3-3 protein sigma (stratifin) (epithelial cell marker protein 1). SW:143T_HUMAN + - P27348 14-3-3 protein tau (14-3-3 protein theta) (14-3-3 protein t-cell) (hs1 protein). 14-3-3 protein zeta/delta (protein kinase c inhibitor protein-1) (kcip-1) (factor SW:143Z_HUMAN + + P29312 P29213 activating exoenzyme s) (fas). P01889 Q29638 Q29681 Q29854 Q29861 Q31613 hla class i histocompatibility antigen, b-7 alpha chain precursor (mhc class i antigen SW:1B07_HUMAN + - Q9GIX1 Q9TP95 b*7). hla class i histocompatibility antigen, b-14 alpha chain precursor (mhc class i antigen SW:1B14_HUMAN + - P30462 O02862 P30463 b*14). P30479 O19595 Q29848 hla class i histocompatibility antigen, b-41 alpha chain precursor (mhc class i antigen SW:1B41_HUMAN + - Q9MY79 Q9MY94 b*41) (bw-41). hla class i histocompatibility antigen, b-42 alpha chain precursor (mhc class i antigen SW:1B42_HUMAN + - P30480 P79555 b*42). P30488 O19615 O19624 O19641 O19783 O46702 hla class i histocompatibility antigen, b-50 alpha chain precursor (mhc class i antigen SW:1B50_HUMAN + - O78172 Q9TQG1 b*50) (bw-50) (b-21). hla class i histocompatibility antigen, b-54 alpha chain precursor (mhc class i antigen SW:1B54_HUMAN + - P30492 Q9TPQ9 b*54) (bw-54) (bw-22). P30495 O19758 P30496 hla class i histocompatibility antigen, b-56 alpha chain precursor (mhc class i antigen SW:1B56_HUMAN - + P79490 Q9GIM3 Q9GJ17 b*56) (bw-56) (bw-22).
    [Show full text]
  • Peptide Sequence
    Peptide Sequence Annotation AADHDG CAS-L1 AAEAISDA M10.005-stromelysin 1 (MMP-3) AAEHDG CAS-L2 AAEYGAEA A01.009-cathepsin D AAGAMFLE M10.007-stromelysin 3 (MMP-11) AAQNASMW A06.001-nodavirus endopeptidase AASGFASP M04.003-vibriolysin ADAHDG CAS-L3 ADAPKGGG M02.006-angiotensin-converting enzyme 2 ADATDG CAS-L5 ADAVMDNP A01.009-cathepsin D ADDPDG CAS-21 ADEPDG CAS-L11 ADETDG CAS-22 ADEVDG CAS-23 ADGKKPSS S01.233-plasmin AEALERMF A01.009-cathepsin D AEEQGVTD C03.007-rhinovirus picornain 3C AETFYVDG A02.001-HIV-1 retropepsin AETWYIDG A02.007-feline immunodeficiency virus retropepsin AFAHDG CAS-L24 AFATDG CAS-25 AFDHDG CAS-L26 AFDTDG CAS-27 AFEHDG CAS-28 AFETDG CAS-29 AFGHDG CAS-30 AFGTDG CAS-31 AFQHDG CAS-32 AFQTDG CAS-33 AFSHDG CAS-L34 AFSTDG CAS-35 AFTHDG CAS-L36 AGERGFFY Insulin B-chain AGLQRGGG M14.004-carboxypeptidase N AGSHLVEA Insulin B-chain AIDIDG CAS-L37 AIDPDG CAS-38 AIDTDG CAS-39 AIDVDG CAS-L40 AIEHDG CAS-L41 AIEIDG CAS-L42 AIENDG CAS-43 AIEPDG CAS-44 AIEQDG CAS-45 AIESDG CAS-46 AIETDG CAS-47 AIEVDG CAS-48 AIFQGPID C03.007-rhinovirus picornain 3C AIGHDG CAS-49 AIGNDG CAS-L50 AIGPDG CAS-L51 AIGQDG CAS-52 AIGSDG CAS-53 AIGTDG CAS-54 AIPMSIPP M10.051-serralysin AISHDG CAS-L55 AISNDG CAS-L56 AISPDG CAS-57 AISQDG CAS-58 AISSDG CAS-59 AISTDG CAS-L60 AKQRAKRD S08.071-furin AKRQGLPV C03.007-rhinovirus picornain 3C AKRRAKRD S08.071-furin AKRRTKRD S08.071-furin ALAALAKK M11.001-gametolysin ALDIDG CAS-L61 ALDPDG CAS-62 ALDTDG CAS-63 ALDVDG CAS-L64 ALEIDG CAS-L65 ALEPDG CAS-L66 ALETDG CAS-67 ALEVDG CAS-68 ALFQGPLQ C03.001-poliovirus-type picornain
    [Show full text]
  • Mirnas Documented to Play a Role in Hematopoietic Cell Lineage. Our
    Table S1: miRNAs documented to play a role in hematopoietic cell lineage. Our review of the literature summarizing miRNAs known to be involved in the development and proliferation of the hematopoietic lineage cells. miRNA Expression/function/target/regulator References miR-150 Elevated during developmental stages of B and T cell maturation. 16-19 Controls B cell differentiation, present in mature, resting T and B cells but decreased upon activation of naïve T or B cells. Plays a role in establishing lymphocyte identity. Very little is known about function in T cells. Regulators: Foxp3 Target: C-Myb miR-146a/b Upregulated in macropgahe inflammatory response. Differentially 17, 20 upregulated in murine Th1 subset but abolished in Th2 subset. Upregulated in response to TCRs stimulation, as well as by IL-1 and TNF. Highly expressed in murine T-regs and could play a role in establishing lymphocyte identity. Modulates activation induced cell death in activated T cells. Negative regulator of TLR and cytokine signaling pathway. Endotoxin tolerance. Antiviral role. Targets: IRAK1, IRAK2, TRAF6, FAF1 miR-16-1 Promote apoptosis by targeting Bcl2 expression, act as tumor 22 cluster suppressor RNAs. May block differentiation of later stage hematopoietic progenitor cells to mature cells. Downregulated in CLL. Target: BCL2. miR-155 Regulator of T and B cell maturation and innate immune response. 23-29 Expressed in primary mediastinal B-cell lymphoma, T and B cells, macrophages and DCs. Upregulated during B cell activation. Involved in T cell differentiation and indicated as a positive regulator of cytokine production. Activated by stimulating TLR3 and INFab receptors in bone derived macrophages (regulation of antimicrobial defense).
    [Show full text]
  • Dysregulation of Bacterial Proteolytic Machinery by a New Class of Antibiotics
    ARTICLES Dysregulation of bacterial proteolytic machinery by a new class of antibiotics Heike Bro¨tz-Oesterhelt1, Dieter Beyer1, Hein-Peter Kroll1, Rainer Endermann1, Christoph Ladel1, Werner Schroeder2, Berthold Hinzen3, Siegfried Raddatz3, Holger Paulsen3, Kerstin Henninger4, Julia E Bandow5, Hans-Georg Sahl6 & Harald Labischinski1 Here we show that a new class of antibiotics—acyldepsipeptides—has antibacterial activity against Gram-positive bacteria in vitro and in several rodent models of bacterial infection. The acyldepsipeptides are active against isolates that are resistant to antibiotics in clinical application, implying a new target, which we identify as ClpP, the core unit of a major bacterial protease complex. ClpP is usually tightly regulated and strictly requires a member of the family of Clp-ATPases and often further accessory http://www.nature.com/naturemedicine proteins for proteolytic activation. Binding of acyldepsipeptides to ClpP eliminates these safeguards. The acyldepsipeptide- activated ClpP core is capable of proteolytic degradation in the absence of the regulatory Clp-ATPases. Such uncontrolled proteolysis leads to inhibition of bacterial cell division and eventually cell death. Worldwide spread of antibiotic resistance greatly impairs the treat- (Table 1). Gram-negative bacteria were only affected when efflux ment of life-threatening infections and antibacterial agents with new pumps were deleted or permeabilizing agents were added to the mechanisms of action are urgently needed1,2. Among Gram-positive culture broth, indicating that penetration across the outer membrane bacteria, multidrug-resistant isolates of Staphylococcus aureus, Strepto- is hampered, as expected for molecules of that size. coccus pneumoniae and Enterococcus cause special concern because of their rising prevalence in hospitals and community settings2–5.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Insights Into the Genomic and Metabolic Adaptations of Termite
    INSIGHTS INTO THE GENOMIC AND METABOLIC ADAPTATIONS OF TERMITE ASSOCIATED VERRCUCOMICROBIA STRAINS USING FUNCTIONAL AND COMPARATIVE GENOMICS by Malini Kotak Presented to the Faculty of the Graduate School of The University of Texas at Arlington in Partial Fulfillment of the Requirements for the Degree of DOCTOR OF PHILOSOPHY THE UNIVERSITY OF TEXAS AT ARLINGTON DECEMBER 2016 Copyright © by Malini Kotak 2016 All Rights Reserved II Acknowledgements I would like to express my sincere gratitude to Dr. Jorge L. M. Rodrigues for being my mentor and providing opportunities, encouragement, guidance and support throughout my doctoral studies. I thank him for believing in me and pushing me beyond what I thought were my limits. Next, I would like to thank Dr. Demuth for agreeing to be my supervisor, and giving me an opportunity to finish my dissertation. I especially thank him for patiently answering all my questions regarding evolutionary and computational biology. I would like to thank Dr. Chrz for letting me use his lab, and for thought provoking conversations about microbial physiology. I am also thankful to Dr. Grover and Dr. Christensen for finding time amidst their busy schedule to guide me. Needless to mention, science is a collaborative endeavor and I would like to express my immense gratitude to all the erstwhile scientists who have worked hard to bring human knowledge to where it stands. I am humbled to have had the chance to be able to contribute to this collaborative effort. Completing my Ph. D. studies would have been very difficult without support form the Biology Department personnel including Linda, Gloria, Paulette, Sherri, Sufera, Kim, Melissa and Anya.
    [Show full text]
  • Peptidases: a View of Classification and Nomenclature
    Proteases: New Perspectives V. Turk (ed.) © 1999 Birkhauser Verlag Basel/Switzerland Peptidases: a view of classification and nomenclature Alan 1. Barrett MRC Molecular Enzymology Laboratory, The Babraham Institute, Cambridge CB2 4AT, UK Introduction It is beyond question that the results of research on proteolytic enzymes, or peptidases, are already benefiting mankind in many ways, and there is no doubt that research in this area has the potential to contribute still more in the future. One of the clearest indications of the gener­ al recognition of this promise is the vast annual expenditure of the pharmaceutical industry on exploring the involvement of peptidases in human health and disease. The high and accelerating rate of research on peptidases is being rewarded by a rate of dis­ covery that could not have been imagined just a few years ago. One measure of this is the num­ ber of known peptidases. At the present time, we can recognise perhaps 600 distinct peptidas­ es, including over 200 that are expressed in mammals, and new ones are being discovered almost daily. This means that there is a clear need for sound systems for classifying the enzymes and for naming them. Only with such systems in place can the wealth of new information that is becoming available be shared efficiently amongst the many scientists now active in this field of research. Without such systems, there will be needless and expensive duplication of effort, and the rate of discovery, and its consequent benefits to mankind, will be slower. The justifi­ cation for trying to improve the systems is therefore strictly practical, and most of the questions that arise are best dealt with by asking what will be most useful to the scientists working in the field, not by reference to any abstract theory.
    [Show full text]